Loading GEHC detail
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally.
The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Chart data unavailable

GE HealthCare teams with Medtronic to integrate real-time imaging in cranial surgery, aiming to enhance precision, workflows and clinician decision-making.

The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced a digital integration between the GE HealthCare bkActiv™ intraoperative ultrasound (iUS) system and the Medtronic Stealth AXiS™ surgical navigation system, which is now commercially available to provide real-time advanced imaging during cranial procedures to complement surgical planning and navigation workflows. This integration builds on an existing strategic alliance between the companies to accelerate next-generation technology innovati.

Asio Capital LLC cut its stake in GE HealthCare Technologies Inc. (NASDAQ: GEHC) by 13.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,908 shares of the company's stock after selling 8,207 shares during the period. Asio Capital LLC's holdings

Glucose Health (OTCMKTS:GLUC - Get Free Report) and GE HealthCare Technologies (NASDAQ: GEHC - Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation. Profitability This table compares Glucose Health and

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will announce its first quarter 2026 financial results before the market opens on Wednesday, April 29, 2026. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will.

GE HealthCare (GEHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and Abbott (ABT). But which of these two stocks is more attractive to value investors?

CHICAGO--(BUSINESS WIRE)--GE HealthCare Technologies Inc. (Nasdaq: GEHC) (the “Company” or “GE HealthCare”) announced today that it received notice on March 30, 2026, of an unsolicited “mini-tender” offer by Potemkin Limited to purchase up to 100,000 shares of GE HealthCare common stock at a price of $45.80 per share in cash. Potemkin Limited's offer price of $45.80 per share is approximately 34.80 percent lower than the $70.25 closing per share price of GE HealthCare's common stock on March 18.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Shares of GE HealthCare Technologies Inc. (NASDAQ: GEHC - Get Free Report) have earned a consensus rating of "Hold" from the fourteen brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to

Eagle Rock Investment Company LLC decreased its stake in GE HealthCare Technologies Inc. (NASDAQ: GEHC) by 50.1% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 29,262 shares of the company's stock after selling 29,405 shares during the period.

GE HealthCare (GEHC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

/PRNewswire/ -- USANewsGroup.com News Commentary - Heart disease is a quiet crisis that is draining healthcare resources worldwide, currently costing the